Clinical trials: Cemiplimab, completed
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Renal Cell Carcinoma
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
- Trial name
- NCT03294083
- Testing
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 95 people
- Sponsor
- SillaJen, Inc.
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
- Trial name
- NCT03889912
- Testing
- Cemiplimab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Regeneron Pharmaceuticals
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Study of Cemiplimab in Adults With Cervical Cancer
The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either…
- Trial name
- NCT03257267
- Testing
- Cemiplimab, Investigator Choice (IC) Chemotherapy
- Where
- 105 sites in United States, Australia and 12 more
- Volunteers
- 608 people
- Sponsor
- Regeneron Pharmaceuticals
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Malignancies
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in…
- Trial name
- NCT03005782
- Testing
- REGN3767, cemiplimab
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 333 people
- Sponsor
- Regeneron Pharmaceuticals
Hormone Receptor-positive Breast Cancer
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.
- Trial name
- NCT05064085
- Testing
- Cemiplimab, Capecitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cutaneous Squamous Cell Carcinoma
Real World Study on the Use of Cemiplimab in Adult Patients in UK
The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated…
- Trial name
- REACT-CEMI (NCT05493826)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- Sanofi
Cancer, Immune-related Adverse Event
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database.
- Conditions
- Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- EXIT (NCT05934214)
- Testing
- Immune checkpoint inhibitor
- Where
- 2 sites in France
- Volunteers
- 141,630 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810).
- Trial name
- CLIO-1 (NCT02651662)
- Testing
- cemiplimab, odronextamab
- Where
- 30 sites in United States, Austria and 4 more
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Toxicity From ICI Therapy
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to…
- Trial name
- NCT04898751
- Testing
- Immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 2,214 people
- Sponsor
- Johns Hopkins University
Cancer/Squamous Cell Carcinoma of Skin
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
Primary Objective: -Assess the effectiveness of cemiplimab versus other available systemic therapies in patients up to 2018 or say historical system organ class (SOC) with metastatic or locally advanced cutaneous Squamous Cell…
- Trial name
- TOSCA (NCT05302297)
- Testing
- Cemiplimab
- Where
- France
- Volunteers
- 305 people
- Sponsor
- Sanofi
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Cemiplimab in AlloSCT/SOT Recipients With CSCC
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney…
- Trial name
- CONTRAC (NCT04339062)
- Testing
- Cemiplimab, Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute